New U.S. pharmaceutical tariffs will increase costs, disrupt sourcing strategies, and force manufacturers to rethink how global drug supply chains are structured.

A Structural Shift, Not a Policy Event

New U.S. tariffs on imported pharmaceuticals are set to introduce cost pressure and uncertainty across one of the most globally integrated supply chains. The United States imports roughly $200–$250 billion in pharmaceutical products annually, much of it tied to patented, high-value therapies produced in Europe and Asia. Even moderate tariffs will materially affect these flows.

For manufacturers, this is not a temporary pricing issue. It directly affects sourcing decisions, manufacturing footprints, and long-term network design. Pharmaceutical supply chains have been built over decades to balance efficiency, regulatory compliance, and specialized production capabilities. Tariffs introduce friction into that system. Products with tightly managed pricing and margins are particularly exposed.

This is now a supply chain design problem.

The API Constraint

The most immediate vulnerability sits upstream in active pharmaceutical ingredients. Roughly 70–80 percent of global API production is concentrated in India and China, and many Western manufacturers depend heavily on those sources. That dependency is not easily unwound.

If tariffs extend upstream, the impact broadens quickly. Cost structures shift across entire product portfolios, supplier substitution becomes limited, and lead times increase as companies navigate regulatory approvals and validation requirements. Moving API production for a complex molecule can take three to five years. That constraint alone limits how quickly supply chains can adjust.

APIs remain the most exposed and least flexible layer of the pharmaceutical supply chain.

Pharmaceutical Supply Chains as Strategic Infrastructure

This policy direction reflects a broader shift. Pharmaceutical supply chains are increasingly being treated as strategic infrastructure, similar to semiconductors and energy. The U.S. has already identified more than 100 essential medicines with supply chain vulnerabilities, and policy actions are beginning to align with that assessment.

The direction is clear. Governments are likely to continue intervening, domestic capacity will receive support, and regionalization will accelerate. Supply chain strategy is no longer driven solely by cost and service. Policy is now a primary variable.

Reshoring Will Be Slow and Selective

Tariffs improve the economics of domestic production, but reshoring pharmaceuticals is slow and capital-intensive. A new manufacturing facility can require hundreds of millions to several billion dollars in investment and may take five to ten years to become fully operational.

Most companies will not make abrupt shifts. Instead, they will take a more measured approach. Domestic capacity will expand selectively, particularly for high-priority products. Sourcing will become more diversified across regions, and reliance on any single geography will be reduced.

The likely outcome is not full reshoring, but a more distributed and actively managed network.

Contract Manufacturing as the Near-Term Lever

In the near term, the fastest adjustment comes through the contract manufacturing network. Pharmaceutical companies already rely heavily on outsourced production, and shifting volume across existing partners can be executed far more quickly than building new facilities.

This flexibility makes contract manufacturing the most practical lever for reducing tariff exposure. It allows companies to rebalance production geographically without committing to long-term capital investments.

Global Response and Network Fragmentation

Pharmaceutical supply chains are deeply interconnected, and any unilateral tariff action carries the risk of response. The European Union alone exports more than $80 billion in pharmaceuticals annually to the United States, making it highly exposed to policy changes.

Responses could take multiple forms, including trade countermeasures, regulatory adjustments, or incentives to retain manufacturing. Regardless of the specific actions, the result is likely to be greater fragmentation. Trade environments become more complex, compliance requirements increase, and the ability to optimize globally diminishes.

The system becomes less stable and more difficult to manage.

Cost Pressure and Service Risk

Tariffs introduce cost increases that are difficult to absorb. Branded pharmaceutical pricing is often constrained by regulatory or contractual structures, while generics operate on already thin margins. That combination limits pricing flexibility.

As costs rise, supply risks increase. Lower-margin products may see reduced supplier participation, and reliance on fewer sources can increase vulnerability. The U.S. has already experienced shortages in areas such as antibiotics and oncology drugs. Additional cost pressure only raises that risk.

At the same time, service levels must remain intact. For critical drugs, disruption is not an option. Supply chain leaders are left managing cost and continuity at the same time.

Technology Becomes Central to Decision-Making

This environment cannot be managed with static planning models. Tariffs introduce variability that requires continuous scenario evaluation and rapid adjustment.

Companies will need stronger capabilities in network design, planning, trade compliance, and supplier visibility. The goal is not just optimization, but adaptability. Leaders need to understand how cost structures shift under different policy scenarios and how quickly they can respond.

This aligns with the broader transition toward more intelligent, responsive supply chains, where decision-making is dynamic rather than fixed .

Organizations that lack these capabilities will be slower to respond and more exposed to disruption.

Signal vs. Reality

The signal is that tariffs will bring pharmaceutical manufacturing back to the United States. The reality is more nuanced. Most production will remain global, but supply chains will become more regional, more redundant, and more expensive to operate.

A More Regional and Resilient Model

The pharmaceutical supply chain is not being dismantled. It is being restructured. Global networks will remain in place, but they will be supplemented with regional capacity and additional redundancy.

Geographic diversification will increase. Trade exposure will be managed more actively. Cost efficiency will remain important, but resilience will carry equal weight in decision-making.

The Bottom Line

Pharmaceutical tariffs mark a structural shift in how drug supply chains are designed and managed. This is no longer a procurement issue or a pricing issue. It is a network design and risk management challenge.

The companies that can model scenarios, adapt their networks, and maintain service levels will be better positioned. Those that move slowly will face higher costs, greater risk, and reduced flexibility.

This is not a short-term tariff cycle. It is the beginning of a more controlled, more regional, and more complex pharmaceutical supply chain model.

The post Pharmaceutical Tariffs and the Restructuring of Global Drug Supply Chains appeared first on Logistics Viewpoints.

Manual trailer and ocean-container unloading remains one of the most ergonomically challenging activities in warehousing and distribution operations. The work is highly repetitive and, in many operations, is associated with higher injury risk and inconsistent staffing, making inbound receiving a persistent capacity constraint rather than a short-term labor disruption. In a recent briefing with Contoro Robotics, this dynamic was clear: when the limiting factor is the manual handling of floor-loaded cartons inside trailers and ocean containers, the value proposition for robotics—measured in throughput stability, safety performance, and labor availability—can become compelling.

For end users, the issue extends beyond unload rate. Safety risk, absenteeism, turnover, and process variability all increase when operations rely on workers to lift, twist, and reach within confined trailers for an entire shift. Conditions also matter: during summer months, temperatures inside containers can reach extreme levels, which can affect retention and staffing reliability. These pressures are driving interest in solutions that remove the highest-strain tasks from the workflow while keeping people focused on supervision, exception management, and value-added downstream activities.

Source: Boston Dynamics

Why Contoro Robotics is a relevant market signal

Contoro Robotics is noteworthy because it is targeting a well-defined, high-friction segment of the intralogistics value chain: autonomous (or semi-autonomous) unloading of floor-loaded trailers and ocean containers. By employing a human-in-the-loop operating model, the approach acknowledges real-world variability while still enabling meaningful labor displacement in the most demanding portion of inbound receiving. The positioning centers on improved ergonomics, reduced labor dependence, and scalable throughput—outcomes that directly support faster dock-to-stock performance and more predictable receiving operations.

More broadly, labor market conditions are reshaping automation investment criteria. Buyers are increasingly prioritizing solutions that reduce physical strain, stabilize throughput, and improve operational resilience—particularly in processes where staffing volatility directly impacts service levels. Unloading-focused robotic systems that can operate within trailers, accommodate variability in carton size and condition, and integrate with existing material handling equipment (MHE) and execution layers such as warehouse management systems / warehouse control systems (WMS/WCS) are easier to justify because they avoid wholesale facility redesign while still delivering a credible ROI and TCO improvement.

Robotic picking in intralogistics: definition and scope

Within intralogistics, robotic picking refers to the use of robots to identify, grasp, and place items or cartons as part of internal material flows. These solutions typically combine 3D vision/perception, AI-based recognition and grasp planning, industrial robot arms, and application-specific end effectors to execute tasks such as piece picking, depalletizing, singulation, or unloading of floor-loaded trailers and ocean containers.

The primary value proposition is improved productivity and process consistency under challenging labor conditions. When properly engineered and integrated, robotic picking can increase effective throughput, reduce labor exposure in high-strain tasks, and improve operational predictability across shifts and peak periods. In many facilities, these systems help reduce touchpoints between inbound receiving and downstream fulfillment by automating repetitive handling steps while reserving people for exceptions, quality checks, and flow supervision.

Key market drivers

Several factors are accelerating adoption of robotic picking. First, chronic labor scarcity, high turnover, and rising wage pressure make it difficult to staff the most physically demanding jobs with acceptable stability. Second, operators are seeking faster dock turns and more deterministic inbound flow; automation can reduce the variability inherent in manual unloading. Third, advances in perception, AI-based grasp planning, and end-effector design have expanded the range of real-world packages and mixed loads that robots can handle reliably.

At the same time, buying behavior is shifting toward deployment pragmatism. End users are less interested in technology demonstrations and more focused on solutions that can be implemented in brownfield environments, integrate with existing processes, and deliver measurable performance against agreed KPIs. Container and trailer unloading is an attractive entry point because the business case is often visible in multiple dimensions—labor reduction, improved ergonomics, higher inbound throughput, and a clearer path to ROI.

Representative use cases in intralogistics

Robotic picking is being applied across a range of material handling tasks. Inbound unloading of floor-loaded ocean containers is gaining priority because it is physically demanding and frequently constrains receiving capacity. Piece picking (from totes, bins, or shelves) is also a major segment, particularly in e-commerce and omnichannel fulfillment where SKU proliferation and service-level requirements pressure operations to increase pick rates and accuracy.

Source: KUKA Robotics

Common applications include:

Unloading of floor-loaded trailers and ocean containers (cartons/cases).
Piece picking from totes, bins, or storage locations for order fulfillment.
Depalletizing and transfer to conveyors, sortation, or put-wall processes.
Mixed-SKU handling in retail, e-commerce, and third-party logistics (3PL) operations.

Solutions that gain traction typically combine robust perception and grasp capabilities with operational workflows for exceptions, including human oversight where required. In many environments, this semi-autonomous approach delivers better real-world availability and faster time-to-value than designs that assume full autonomy under all load conditions—particularly when carton geometry, packaging materials, and load quality vary significantly.

ARC perspective

Robotic picking should be viewed less as a wholesale replacement for warehouse labor and more as a targeted strategy to remove the most physically taxing, variable, and difficult-to-staff tasks from core material flows. The Contoro Robotics briefing reinforces an important point: inbound floor-loaded unloading is both a significant source of labor pain and an increasingly addressable automation opportunity. As this segment matures, ARC expects evaluation criteria to center on deployability, integration with existing execution systems, and performance against KPIs such as inbound throughput, dock-to-stock time, safety metrics, and total cost of ownership.

The post Labor Constraints are Accelerating Adoption of Dock Automation and Robotic Picking appeared first on Logistics Viewpoints.

For the past several years, artificial intelligence has been everywhere in enterprise conversations and nowhere in actual results. Most organizations have experimented, many have piloted, but very few have operationalized AI in a way that meaningfully moves the needle. In fact, the numbers tell a sobering story: the vast majority of enterprise AI initiatives fail to deliver tangible business value, with estimates suggesting as many as 80 to 95% fall short of expectations.

For enterprise leaders, this gap between promise and performance isn’t just frustrating, it is costly. It also raises an important question: why has AI struggled to deliver despite the explosion of internal and external data, and the significant technology investments made to support enterprise processes and teams?

The answer lies less in the technology itself and more in how it’s being applied across real-world, interconnected operations. Most organizations are not failing because AI doesn’t work, but because of fragmented data, siloed processes, and the challenge of integrating AI into existing systems and workflows.

Why AI Struggles in Real-World Operations

If the first wave of AI was about prediction, the next wave is about action. Leading organizations are moving beyond static models toward systems that can sense, analyze, decide, and act in near real time, often described as agentic capabilities. These systems do not just generate insights; they participate directly in execution.

We are already seeing what this looks like in practice. In fast-moving consumer sectors, AI-driven approaches are compressing product development cycles from months to days by linking demand signals directly to design and supply decisions. In retail and food service, digital twin environments are enabling teams to simulate disruptions and resolve them in minutes instead of days, reducing manual effort while improving service levels and inventory efficiency.

The common thread is the integration of AI into the operational fabric of the business. Four characteristics stand out:

A shared, semantic understanding of the business – Enterprise intelligence is built on a unified representation of the business across structured and unstructured data, enabling AI to understand how information, decisions, and outcomes are connected.
Workflow-driven simulation and execution – AI must operate within real business processes, simulating outcomes across workflows and applying business logic to guide decisions from planning through execution.
Orchestrated decision-making across the enterprise – An orchestration layer connects people, data, and systems, enabling more collaborative, informed decisions and ensuring those decisions can be executed across existing systems of record.
Continuous learning and improvement – AI systems must continuously learn from outcomes, improving decision quality over time and adapting to changing conditions.

For all its sophistication, AI must also feel simple to the user. The underlying complexity does not disappear, but it must be abstracted. The real test is whether organizations can deliver accurate, real-time answers without exposing the complexity that makes them possible.

Increasingly, this also means making these capabilities accessible beyond technical teams, through self-service environments that allow business users to define, test, and adapt decision processes without relying entirely on specialized development resources.

Why Supply Chains Are the Proving Ground for Enterprise AI

Supply chains reflect the operational “physics” of the enterprise and are among its most consequential domains. Every decision, what to make, where to ship, how much to hold, has direct financial and customer impact. That complexity, when fragmented and managed in silos, is precisely why AI has struggled here. It is also why success in supply chains matters more than anywhere else.

But the implications go beyond supply chains alone. The highest-value opportunities are centered on solving these challenges because they are foundational to how enterprises operate. Supply chains are simply the most demanding proving ground for a broader shift toward real-time, connected decision-making across the business.

We are now at an inflection point. Advances in data architecture, cloud scalability, and AI techniques are converging to make enterprise-grade deployment practical. At the same time, market momentum is accelerating, with investment in enterprise AI outpacing traditional software categories and signaling a long-term shift in how organizations operate. For leaders, this creates both urgency and opportunity.

The lesson from the past few years is clear: isolated AI projects do not scale. Incremental experimentation alone will not get organizations where they need to go. What is required instead is a system-level approach that connects data, decisions, and execution across the end-to-end enterprise. This is where orchestration becomes critical.

Orchestration is not about replacing planning. It is about elevating it by connecting planning with execution, aligning decisions across functions, and ensuring that AI operates within the full context of the business. It enables organizations to move from reacting to disruptions to proactively managing them.

From a technology perspective, this means building environments where data, AI models, business rules, and human expertise coexist, and where decisions can be simulated, tested, and executed in a continuous loop.

From an organizational perspective, it requires rethinking how teams work. The most successful companies are investing in cross-functional capabilities, bringing together domain experts, data scientists, and operators to translate AI potential into operational reality. What’s emerging is not just a new set of tools, but a new operating layer that connects decisions across the enterprise.

From AI Experimentation to Enterprise Impact

AI in enterprise is no longer a question of “if.” It is a question of “how.” The hype cycle is giving way to a more pragmatic phase focused on measurable outcomes, operational integration, and sustained value creation.

Organizations that continue to treat AI as a series of experiments will fall behind, while those that embed it into the core of how they operate will gain a meaningful competitive edge.

McKinsey’s research reinforces this divide. High performers are nearly three times more likely than others to redesign workflows around AI, rather than simply layering it onto existing processes, and are significantly more likely to view AI as a driver of enterprise-wide transformation.

The path forward is not about chasing the next breakthrough model. It is about building the

foundation for continuous, connected decision-making and execution at scale. In complex operations, value does not come from knowing more. It comes from consuming data, contextualizing it, analyzing it, making decisions, and acting on them.

By Manik Sharma, Chief of Agentic Solutions, Kinaxis

Manik is a seasoned supply chain and digital transformation leader, bringing more than 30 years of experience driving operational and organizational change across industries and global markets. He is known for building and scaling go-to-market strategies, accelerating sales momentum, and delivering measurable customer value through strong cross-functional orchestration.

Currently Chief of Agentic Solutions at Kinaxis, he leads the development and execution of AI-driven strategies that help organizations transform decision-making and operational performance. His career spans leadership roles at Celonis, Palantir, Coupa, and previously Kinaxis, where he has consistently driven growth, innovation, and customer impact.

His expertise includes digital transformation, supply chain management, advanced analytics, and enterprise strategy, with a focus on helping organizations adapt and compete in increasingly complex environments.

The post From AI Experiments to Operational Impact: What It Really Takes for Enterprises to Realize Value appeared first on Logistics Viewpoints.